Mostrar el registro sencillo del ítem

dc.contributor.author Hugger, Sarah Sonja
dc.contributor.author Do, Thien Phu
dc.contributor.author Ashina, Håkan
dc.contributor.author Goicochea, María Teresa
dc.contributor.author Jenkins, Bronwyn
dc.contributor.author Sacco, Simona
dc.contributor.author Lee, Mi Ji
dc.contributor.author Brennan, K. C.
dc.contributor.author Amin, Faisal Mohammad
dc.contributor.author Steiner, Timothy J.
dc.contributor.author Ashina, Messoud
dc.date.accessioned 2024-03-07T13:03:11Z
dc.date.available 2024-03-07T13:03:11Z
dc.date.issued 2023-09-20
dc.identifier.citation Hugger SS, Do TP, Ashina H, Goicochea MT, Jenkins B, Sacco S, Lee MJ, Brennan KC, Amin FM, Steiner TJ, Ashina M. Migraine in older adults. Lancet Neurol. 2023 Oct;22(10):934-945. doi: 10.1016/S1474-4422(23)00206-5 es_ES
dc.identifier.uri https://doi.org/10.1016/S1474-4422(23)00206-5
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/1034
dc.description.abstract Migraine is an evolving, and sometimes lifelong disorder. The prevalence of episodic migraine peaks among individuals aged in their late 30s, implying a tendency for the disorder to remit with increasing age thereafter, whereas chronic migraine is more likely to persist into later life. Diagnosis and treatment of migraine in older adults, defined as individuals aged 60 years or older, is rendered more complex by increasing probabilities of atypical clinical features and comorbidities, with patients' comorbidities sometimes limiting their therapeutic options. However, the changing clinical presentation of migraine over an individual's lifespan is not well characterised. The neurobiological basis of remission in older adults remains unclear, although vascular, neuronal, and hormonal changes are likely to be involved. Long-term longitudinal studies of individuals with migraine would be particularly informative, with the potential not only to suggest new research directions, but also to lead to the identification of novel therapeutic agents. Although several novel migraine medications are becoming available, their effectiveness, tolerability, and safety often remain uncertain in older adults, who have commonly been excluded from the evaluation of these agents in randomised controlled trials, or who constitute only a small proportion of study populations. There is a need to recognise these limitations in the available evidence, and the specific, and often unmet, clinical needs of older adults with migraine, not least because older adults constitute an increasing proportion of populations worldwide. es_ES
dc.language.iso eng es_ES
dc.publisher Elsevier es_ES
dc.subject Migraine Disorders es_ES
dc.subject Trastornos Migrañosos es_ES
dc.subject Neurobiology es_ES
dc.subject Neurobiología es_ES
dc.subject Probability es_ES
dc.subject Probabilidad es_ES
dc.subject Randomized Controlled Trials as Topic es_ES
dc.subject Ensayos Clínicos Controlados no Aleatorios como Asunto es_ES
dc.title Migraine in older adults es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.description.fil Fil: Goicochea., María Teresa. Fleni. Departamento de Neurología. Clínica del Dolor. Clínica de Cefaleas; Argentina.
dc.relation.ispartofVOLUME 22
dc.relation.ispartofNUMBER 10
dc.relation.ispartofPAGINATION 934-945
dc.relation.ispartofCOUNTRY Reino Unido
dc.relation.ispartofCITY Londres
dc.relation.ispartofTITLE Lancet Neurology
dc.relation.ispartofISSN 1474-4465
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Listar

Mi cuenta

Estadísticas